<unk> , sold under the brand name Evkeeza, is a monoclonal antibody medication for the treatment of homozygous familial hypercholesterolemia (HoFH). Common side effects include nasopharyngitis (cold), influenza-like illness, dizziness, rhinorrhea (runny nose), and nausea. Serious hypersensitivity (allergic) reactions have occurred in the Evkeeza clinical trials.<unk>  binds to the angiopoietin-like protein 3 (ANGPTL3). ANGPTL3 slows the function of certain enzymes that break down fats in the body.<unk>  blocks ANGPTL3, allowing faster break down of fats that lead to high cholesterol.<unk>  was approved for medical use in the United States in February 2021. Regeneron invented<unk>  using the company's VelocImmune® technology, a proprietary genetically-engineered mouse platform endowed with a genetically-humanized immune system to produce optimized fully-human monoclonal antibodies.
Evinacumab
Olaratumab
Emapalumab
Ustekinumab
Evolocumab
Alirocumab
Lanadelumab
Anifrolumab